Exa-cel is slated for an FDA decision in sickle cell disease by Dec. 8, 2023. Because of that, the Gene Editing stocks will likely experience a surge of activities in the coming week, YMYD

1. PRME

2. BEAM

3. CRSP

4. VERV

5. NTLA

6. TWST

[Reference]

"The Food and Drug Administration appears poised to approve the first medical therapy that uses gene-editing to treat a disease."

https://www.npr.org/sections/health-shots/2023/10/31/1208041252/a-landmark-gene-editing-treatment-for-sickle-cell-disease-moves-closer-to-realit